Azienda U.L.S.S.9 - U.O. di Ematologia
About Azienda U.L.S.S.9 - U.O. di Ematologia
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gruppo Italiano Malattie EMatologiche dell'Adulto
11
Fondazione Italiana Linfomi ONLUS
6
Hoffmann-La Roche
4
Incyte Corporation
1
Clinical Trials at Azienda U.L.S.S.9 - U.O. di Ematologia
During the past decade, Azienda U.L.S.S.9 - U.O. di Ematologia conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on
average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
2010-03-01
2010-12-01
Completed
448
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
2011-02-15
2017-10-31
Completed
410
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
2011-07-26
2018-01-31
Terminated
1,418
Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
2012-01-01
2018-07-10
Completed
515
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
2010-11-01
2013-10-01
Completed
50
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
2012-09-11
2019-05-05
Terminated
144
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda U.L.S.S.9 - U.O. di Ematologia"
#1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator and "Janssen-Cilag S.p.A." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Azienda U.L.S.S.9 - U.O. di Ematologia
According to Clinical.Site data, the most researched conditions in "Azienda U.L.S.S.9 - U.O. di Ematologia" are
"Chronic Myeloid Leukemia" (4 trials), "Acute Myeloid Leukemia" (2 trials), "BCR-ABL Positive" (2 trials), "Follicular Lymphoma" (2 trials) and "Non-Hodgkin's Lymphoma" (2 trials). Many other conditions were trialed in "Azienda U.L.S.S.9 - U.O. di Ematologia" in a lesser frequency.
Clinical Trials Intervention Types at Azienda U.L.S.S.9 - U.O. di Ematologia
Most popular intervention types in "Azienda U.L.S.S.9 - U.O. di Ematologia" are "Drug" (15 trials) and "Other" (4 trials). Other intervention types were less common.
The name of intervention was led by "Cyclophosphamide" (2 trials), "Doxorubicin" (2 trials), "Nilotinib" (2 trials), "Obinutuzumab" (2 trials) and "Ponatinib" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Azienda U.L.S.S.9 - U.O. di Ematologia
The vast majority of trials in "Azienda U.L.S.S.9 - U.O. di Ematologia" are
22 trials for "All" genders.
Clinical Trials Status at Azienda U.L.S.S.9 - U.O. di Ematologia
Currently, there are NaN active trials in "Azienda U.L.S.S.9 - U.O. di Ematologia".
1 are not yet recruiting,
6 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 8 completed trials in Azienda U.L.S.S.9 - U.O. di Ematologia,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Azienda U.L.S.S.9 - U.O. di Ematologia, 0 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 6 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".